Lief Labs

Lief Labs is a contract manufacturing company that partners with entrepreneurial firms to create innovative health and wellness brands through comprehensive solutions in product development and manufacturing. Founded in 2008 in Valencia, US, Lief Labs specializes in contract manufacturing for health and wellness products. The company is led by CEO Adel Villalobos, who has a history in entrepreneurship. In August 2021, Lief Labs received recapitalization from Prairie Capital, S2G Ventures, and Skyline Global Partners, although financial terms were not disclosed.

Lief Labs specializes in contract manufacturing solutions tailored for entrepreneurial firms aiming to establish and grow recognizable and innovative brands. The company offers a comprehensive suite of services, including product ideation, formulation, and manufacturing, ensuring that each product meets the highest industry standards. Their facility is cGMP-certified and FDA-registered, allowing them to produce a wide range of products, including dietary supplements and health products, while adhering to strict regulatory guidelines. Lief Labs serves a diverse client base, including brands in the natural products sector, Amazon sellers, and other businesses looking to deliver quality health solutions to consumers.

Their offerings are distributed primarily across North America, with services extending to various regions globally, facilitating "Prime Ready" shipping directly to Amazon Fulfillment Centers in the U. S. Lief Labs operates through a business-to-business (B2B) model, providing manufacturing services to companies across the health and wellness industry. Revenue is generated via contracts with partner organizations for production and shipping of health products, where clients may engage in both one-time orders and ongoing partnerships for product development.

Transaction structures typically involve comprehensive agreements that outline the scope of work, pricing, and delivery timelines. The company's commitment to quality has positioned them favorably among their clients, leading to repeat business and long-term collaborations. Their flagship offerings are designed to cater to the rigorous demands of the market, ensuring that clients can meet their consumers' needs without compromising on quality or compliance. Following the recapitalization in August 2021, Lief Labs plans to enhance its contract manufacturing business and expand brand-building services for clients.

The company is focusing on developing new health products to launch in the coming year and aims to penetrate additional markets, specifically targeting regions in Europe and Asia by 2023. The recent funding will be pivotal in supporting these initiatives, allowing Lief Labs to further invest in their operational capacity and expand their service offerings.